Delcath systems.

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company's proprietary products, HEPZATO Kit (melphalan ...Checkout Delcath Systems Inc (DCTH) earnings results, EPS expectations and actual EPS values for both quarterly and annual periods. Discover whether DCTH beat the street expectations or not?united states. securities and exchange commission. schedule 14a (rule 14a-101) information required in proxy statement. schedule 14a information. proxy statement pursuant to section 14(a) of the securities exchange act of 1934

Annual Reports & Proxy. SEC Filings. Stock Info. FAQs. Analyst Coverage. See a full list of Delcaths Investors and SEC filings, other useful information and other downloadable reports.Nov 8, 2022 · Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company's proprietary percutaneous hepatic perfusion (PHP) system ...

Delcath Systems, Inc. Common Stock (DCTH) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's proprietary percutaneous hepatic perfusion (PHP) system ...

Track Delcath Systems Inc (DCTH) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsMr. Muir joins Delcath Systems with 20 years of sales and marketing experience in the biotherapeutics and medical technology industries. Before joining Delcath, Mr. Muir was Director of U.S. Sales for the Interventional Oncology business unit at BTG, where he played a key role in the success of TheraSphere™ (custom ordered micro-embolic 90Y radiation radio isotope-therapy).Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on ...Delcath Systems, Inc Report this profile Activity We are excited that the NIH has funded our first D-peptide program in cancer immunotherapy. The money is great, but the validation by the ...NEW YORK, Aug. 14, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced that today the US Food and Drug Administration (FDA) approved HEPZATO KIT (melphalan/Hepatic Delivery System) as a liver-directed treatment for adult ...

Delcath Systems, Inc. 27 Mar, 2023, 08:15 ET. Led by Vivo Capital with participation from Logos Capital, BVF Partners LP, Stonepine Capital Management, LLC, Serrado Capital LLC and supported by ...

NEW YORK, Sept. 1, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic …

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Our investigational product – Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) – is designed to administer high-dose chemotherapy to the liver while controlling ...MasterControl Apps is a cloud-based platform that allows you to access and manage your quality and compliance processes from anywhere. You can create, review, approve ...Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today that it raised approximately $35 ...NEW YORK, Aug. 14, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced that today the US Food and Drug Administration (FDA) approved HEPZATO KIT (melphalan/Hepatic Delivery System) as a liver-directed treatment for adult ...About Delcath Systems, Inc. Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's proprietary products, ...Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's proprietary products, HEPZATO KIT ...By Dr. C.H. Weaver M.D. Sep 11, 2023. The Delcath PHP System significantly delayed cancer progression in the liver. The median time to cancer progression in the liver was 214 days among patients treated with the Delcath PHP system compared with 70 days among patients treated with best alternative care. Full results from this …

Firstly, Delcath Systems is preparing for the launch of HEPZATO KIT, following FDA approval for use in metastatic uveal melanoma. Despite a delay, the product is expected to be launched in January ...UNITED STATES. SECURITIES AND EXCHANGE COMMISSION. WASHINGTON, D.C. 20549. SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT . SCHEDULE 14A INFORMATION . Proxy SDelcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company's proprietary products, HEPZATO KIT (Hepzato (melphalan ...See a full list of events and presentations as well as helpful resources covering Delcaths investors and studies in patients with metastatic ocular melanoma.Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company's proprietary percutaneous hepatic perfusion (PHP) system ...Oct 16, 2023 · Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's proprietary products, HEPZATO KIT ... Nov 8, 2022 · Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company's proprietary percutaneous hepatic perfusion (PHP) system ...

NEW YORK, Nov. 15, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee, as a material …hepatic perfusion (PHP) utilizes a double-balloon catheter system (produced by Delcath Systems, New York, NY, USA) positioned percutaneously in the retrohepatic ...

NEW YORK, Nov. 15, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee, as a material …Annual Reports & Proxy. SEC Filings. Stock Info. FAQs. Analyst Coverage. See a full list of Delcaths Investors and SEC filings, other useful information and other downloadable reports.Get More Information. Demographic Patient Caregiver Healthcare Provider Other. HEPZATO KIT™ Now approved by the US Food and Drug Administration.DCTH Earnings Date and Information. Delcath Systems last posted its quarterly earnings data on November 13th, 2023. The reported ($0.61) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by $0.10. The firm had revenue of $0.43 million for the quarter, compared to analyst estimates of $0.68 million.Delcath Systems (NASDAQ:DCTH – Get Free Report) was upgraded by StockNews.com to a “sell” rating in a report released on Tuesday.DCTH has been the topic of a number of other reports. HC Wainwright increased their target price on shares of Delcath Systems from $17.00 to $18.00 and gave the company a “buy” rating in a …Delcath Systems Inc market cap is $63.05M. What is the 52-week high for Delcath Systems Inc? 52 week high is the highest price of a stock in the past 52 weeks, or one year.Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).9 jan. 2014 ... Conclusion. The increased melphalan extraction efficiency of the new filter is expected to decrease systemic melphalan exposure. In addition, ...Delcath Systems disappoints in Q3 with a GAAP EPS miss of $0.62 and a revenue miss of $0.28M, causing shares to drop 2.01%.

Delcath Systems, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 24661P807 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☑ Rule 13d-1(b) ☐ Rule 13d-1(c) ☐ Rule 13d-1(d)

J Surg Oncol. 2018;117:1170–1178. doi: 10.1002/jso.24956. Vogel A, Gupta S, Zeile M, et al. Chemosaturation percutaneous hepatic perfusion: a systematic review. Adv Ther. 2016;33:2122–2138. doi: 10.1007/s12325-016-0424-4. A full list of clinical and scientific publications used by Delcath as well as an option to contact us.

DCTH Earnings Date and Information. Delcath Systems last posted its quarterly earnings data on November 13th, 2023. The reported ($0.61) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by $0.10. The firm had revenue of $0.43 million for the quarter, compared to analyst estimates of $0.68 million.Oct 16, 2023 · NEW YORK, Oct. 16, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the publication of an article entitled "Selective Internal Radiotherapy (SIRT) and Chemosaturation Percutaneous Hepatic Perfusion (CS-PHP) for ... Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today that it raised approximately $35 ...Delcath Systems Closes Private Placement of $6.2 Million NEW YORK, December 13, 2022 — Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the closing of the previously announced private placement with certain accredited …Delcath Systems, Inc. announces FDA approval of HEPZATO KIT for the treatment of adult patients with unresectable hepatic-dominant metastatic uveal melanoma. News release. Delcath Systems, Inc ...Delcath Systems, Inc. (the “Company”) is a specialty pharmaceutical and medical device company focused on oncology. Delcath's proprietary system for chemosaturation is designeDelcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's proprietary percutaneous hepatic perfusion (PHP) system ...Delcath Systems, Inc. at ROTH Capital Partners 29th Annual Growth Stock Conference March 13, 2017. Delcath Systems, Inc. at 2nd Annual Disruptive Growth & Healthcare Conference February 15, 2017. See All Investor Events and Webcasts. Featured NewsAug 15, 2023 · Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's proprietary products, HEPZATO KIT™ ...

About Delcath Systems, Inc. ... Delcath Systems, Inc. is an oncology company, which engages in the treatment of primary and metastatic liver cancers. Its products ...PR Newswire (US) NEW YORK, Oct. 10, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the ...Merit Medical Systems, a leading global manufacturer and marketer of healthcare technology, has announced the expansion of its Maestro microcatheter product line to now include a new longer length for radial embolization procedures. 10. Delcath Systems announces publication of study comparing chemosaturation and SIRTNEW YORK, Aug. 9, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business highlights and financial results for the second quarter ended June 30, 2023.Instagram:https://instagram. nysearca spxshow much is a silver half dollar worthfutures trading strategychipotle stocl Aug 14, 2023 · NEW YORK, Aug. 14, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced that today the US Food and Drug Administration (FDA) approved HEPZATO KIT (melphalan/Hepatic Delivery System) as a liver-directed treatment for adult ... new american funding home equity loanstartengin Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company's proprietary products, HEPZATO™ KIT (melphalan hydrochloride for Injection/Hepatic Delivery System) and CHEMOSAT ® Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP) are designed to administer high-dose chemotherapy to the liver ...Insiders trading at Delcath Systems. Over the last 4 years, insiders at Delcath Systems have traded over $0 worth of Delcath Systems stock and bought 1,064,320 units worth $8,436,426 . The most active insiders traders include Marco Taglietti, Gerard J Michel, and Advisors, Inc. Rosalind.On average, Delcath Systems executives … transunion shareables 2. Patients must weigh ≥ 35 kg (due to possible size limitations with respect to percutaneous catheterization of the femoral artery and vein using the Delcath Hepatic Delivery System). 3. 50% or less histologically or cytologically-proven ocular melanoma metastases in the parenchyma of the liver. 4.Insiders trading at Delcath Systems. Over the last 4 years, insiders at Delcath Systems have traded over $0 worth of Delcath Systems stock and bought 1,064,320 units worth $8,436,426 . The most active insiders traders include Marco Taglietti, Gerard J Michel, and Advisors, Inc. Rosalind.On average, Delcath Systems executives …www.delcath.com. New York, NY. 1 to 50 Employees. Type: Company - Public (DCTH) Revenue: $1 to $5 million (USD) Health Care Products Manufacturing. Competitors: Unknown. A cancer-stricken liver might be a lonely little organ, thanks to Delcath Systems. The development-stage company's technology allows blood infused with chemotherapy …